Durable CR With Lasofoxifene in ESR1+, ER+/HER2- Metastatic Breast Cancer
Matthew P. Goetz, MD, consultant, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the findings from the ELAINE-1 trial.
Genomic Assays Impact Treatment Decisions in Patients With ER+ Breast Cancer
Matthew P. Goetz, MD, discusses how genomic assays can help identify patients with ER–positive breast cancer who will benefit from the addition of chemotherapy to endocrine therapy.
